Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass Index kg/m 8. ± 4.8 7.9 ± 5. 0.47 Diabetes mellitus no. (%) 7 (6.0) (0.) 0.6 Arterial hypertension no. (%) 68 (84.0) 5 (90.) 0.0 Hypercholesterolemia no. (%) Familial disposition no. (%) Active smoker no. (%) 40 (70.0) 6 (.5) 8 (9.0) 78 (74.9) 7 (6.9) 60 (6.) 0.0 0.9 0.9 Previous MI no. (%) Previous bypass surgery no. (%) 8 (9.0) 7 (8.5) 8 (.8) 5 (4.) 0.4 0.04 CPR at admission no. (%) CAD presentation no. (%) 8 (4.0) (0.5) <0.00 0.000 STEMI NSTEMI Unstable angina Stable angina 60 (0.0) 7 (8.5) 4 (.0) 79 (9.5) 55 (4.8) 76 (0.5) 65 (7.5) 75 (47.) Left ventricular EF (%) 49.0 ±. 5.6 ± 0.9 0.000 The table shows the baseline characteristics of the modified vs. non-modified subgroup of patients within the guided treatment cohort. Data presented are means SD or numbers of patients (percentages). CAD, coronary artery disease; CPR, cardiopulmonary reanimation; EF, ejection fraction; NSTEMI, non-st-segment elevation myocardial infarction; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction.
Suppl. Table : Angiographic and procedural characteristics. Characteristic Modified cohort Non-modified P value (n=00) cohort Target vessel no. (%) 0.04 Left main coronary artery 8 (4.0) (.9) Left anterior descending coronary artery 74 (7.0) 60 (4.) Left circumflex coronary artery Right coronary artery Venous bypass graft Multivessel disease no. (%) 5 (6.0) 65 (.5) 7 (85.5) 8 (.8) 0 (7.8) 6 (4.) 5 (84.9) 0.85 Complex (type B or C) lesions no. (%) Bifurcational lesions no. (%) 65 (8.5) 5 (5.5) 7 (7.6) 79 (.) 0.0 0.5 TIMI flow grade before intervention no. (%) <0.00 0 44 (.0) (5.5) 5 (7.5) 0 (55.0) 6 (9.7) 4 (.8) 49 (.) 7 (7.) Type of intervention no. (%) 0.55 Placement of drug-eluting stent Cypher Dual drug-eluting stent* Endeavor Endeavor Resolute Nobori Taxus 84 (9.0) (.6) 6 (8.7) 0 (0.9) (.5) (.6) 4 (9.) 4 (.) 45 (.) 0 (0.0) 8 (8.) 50 (4.6) (.5)
Xience Yukon Choice PC 7 (9.) 46 (5.0) 7 (7.) 76 (.) Placement of bare-metal stent 5 (.5) 5 (.4) Balloon angioplasty (5.5) 4 (6.5) TIMI flow grade after intervention no. (%) 0.4 0 9 (4.5) 89 (94.5) (0.5) (0.5) 6 (.6) 6 (97.) The table shows the angiographic and procedural characteristics of the modified vs. non-modified subgroup of patients within the guided treatment cohort. Data presented are means SD or numbers of patients (percentages). SD, standard deviation; TIMI, Thrombolysis in Myocardial Infarction. * Probucol plus sirolimus eluting stent.
Suppl. Table : Comedication of patients. Medication (at admission) no. (%) Modified cohort Non-modified cohort P value (n=00) Aspirin 7 (58.5) 6 (6.6) 0. Thienopyridines 0 (5.0) 49 (.) 0.55 Insulin treatment 9 (9.5) (8.6) 0.7 Beta-blockers (55.5) 5 (57.9) 0.57 Statin 0 (5.0) 5 (57.9) 0. Calcium channel blocker 45 (.5) 79 (.) 0.74 Coumarin derivatives 4 (7.0) 46 (.4) 0.05 AT receptor blockers 4 (.0) 56 (5.) 0.07 Nitrates 8 (9.0) 7 (7.) 0.47 Diuretics 75 (7.5) 65 (44.5) 0. Proton pump inhibitors 0.5 No PPI 48 (74.0) 84 (76.6) Esomeprazole 6 (.0) 4 (.) Omeprazole 7 (8.5) 8 (7.6) Pantoprazole 8 (4.0) 54 (4.6) Rabeprazole (0.) The table shows the the comedication at admission of the modified vs. non-modified subgroup of patients within the guided treatment cohort. Data presented are numbers of patients (percentages). PPI, proton pump inhibitor. 4
Suppl. Table 4: Clinical outcome. Events, n (%) Modified cohort Non-modified cohort (n=00) P value Combined death/st (.0) 5 (.) >0.99* TIMI major bleeding 0 (5.0) (0.) 0.000* The table shows the primary endpoint (composite of death from any cause or ST) and incidence of bleeding (TIMI major in-hospital) in the different subgroups of our registry at 0 days (control vs. modified vs. non-modified cohort). Data presented are numbers of patients (percentages). ST, stent thrombosis; TIMI, Thrombolysis in Myocardial Infarction. *p-values calculated with Fisher exact test. 5